期刊文献+

普拉克索单用和联用艾司西酞普兰对改善帕金森病患者抑郁症状及生活质量的比较 被引量:18

Comparison of pramipexole monotherapy and combination application of escitalopram to improve depressive symptoms and life quality in Parkinson's disease
原文传递
导出
摘要 目的比较普拉克索单药治疗和联合应用艾司西酞普兰对改善帕金森病患者抑郁及生活质量的疗效。方法 30例帕金森病患者,随机分为单药组和联合用药组,每组15例,分别单用普拉克索0.25 mg,tid或服用普拉克索0.25 mg,tid和艾司西酞普兰10 mg,qd。于治疗前、治疗后第2周及第8周,采用汉密尔顿抑郁(HAMD)评分评定患者的抑郁程度变化,帕金森病综合评分(UPDRS)及39项帕金森病调查问卷评分(PDQ-39)评定生活质量变化。结果治疗后第2周,联合用药组HAMD评分显著低于单药组(P<0.05);治疗后第8周,两组患者在HAMD评分、UPDRS评分及PDQ-39评分均较治疗前明显降低(P<0.05),联合用药组各评分均低于单药组患者(P<0.05)。结论联合应用艾司西酞普兰可在治疗早期明显改善帕金森病患者的抑郁症状,提高患者的生活质量,疗效优于普拉克索单药治疗。 AIM Observe the differences of pramipexole mono-therapy and combination application of escitalopram on depressive symptoms and improve life quality of Parkinson' s disease. METHODS Thirty cases of Parkinson' s disease were randomly divided into mono- therapy group and combination therapy group. Pramipexole 0.25 mg, tid or pramipexole 0.25 rag, tid combined with escitalopram 10 mg, qd were treated in two groups respectively, 15 cases in each group. Hamilton depression (HAMD) score, Unified Parkinson' s Disease Rating Scale (UPDRS) and the 39-item Parkinson' s Disease Questionnaire (PDQ-39) were observed before the treatment, 2 weeks and 8 weeks after the treatment to assessment the change of depress degree and
出处 《中国新药与临床杂志》 CAS CSCD 北大核心 2013年第1期59-62,共4页 Chinese Journal of New Drugs and Clinical Remedies
关键词 普拉克索 艾司西酞普兰 帕金森病 抑郁症 抗抑郁药 pramipexole escitalopram Parkinson diseases depressive disorder antidepressive agents
  • 相关文献

参考文献3

二级参考文献40

  • 1[2]CLARKE CE,GUTTMAN M.Dopamine agonist monotherapy in Parkinson's disease[J].Lancet,2002,360(9347):1767-1769.
  • 2[4]PERACHON S,SCHWARTZ JC,SOKOLOFF P.Functional potencies of new antiparkinsonian drugs at recombinant human dopamine D1,D2 and D3 receptors[J].Eur J Pharmacol,1999,366(2-3):293-300.
  • 3[5]KONDO T.Initial therapy for Parkinson's disease:levodopa vs dopamine receptor agonists[J].J Neurol,2002,249 Suppl 2:Ⅱ25-Ⅱ29.
  • 4[6]JENNER PG,BRIN MF.Levodopa neurotoxicity:experimental studies versus clinical relevance[J].Neurology,1998,50 (6 Suppl 6):S39-S43.
  • 5[7]ZOU L,JANKOVIC J,ROWE D,et al.Neuroprotection by pramipexole against dopamine- and levodopa- induced cytotoxicity[J].Life Sci,1999,64:1275-1285.
  • 6[8]LING ZD,ROBIE HC,TONG CW,et al.Both the antioxidant and D3 agonist actions of pramipexole mediate its neuroprotective actions in mesencephalic cultures[J].J Pharmacol Exp Ther,1999,289(1):202-210.
  • 7[9]TAKASHIMA H,TSUJIHATA M,KISHIKAWA M,et al.Bromocriptine protects dopaminergic neurons from levodopa-induced toxicity by stimulating D2 receptors[J].Exp Neurol,1999,159(1):98-104.
  • 8[10]FERRARIO JE,DELFINO MA,STEFANO AV,et al.Effects of orally administered levodopa on mesencephalic dopaminergic neurons undergoing a degenerative process[J].Neurosci Res,2003,47(4):431-436.
  • 9[11]IIDA M,MIYAZAKI I,TANAKA K,et al.Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole,a dopamine agonist[J].Brain Res,1999,838(1-2):51-59.
  • 10[12]LE WD,JANKOVIC J,XIE W,et al.Antioxidant property of pramipexole independent of dopamine receptor activation in neuroprotection[J].J Neural Transm,2000,107(10):1165-1173.

共引文献21

同被引文献143

  • 1吴盛各,徐健,郭华贵.艾司西酞普兰与帕罗西汀治疗老年脑卒中后抑郁的对照研究[J].黑龙江医学,2013,37(1):8-10. 被引量:13
  • 2吕荣祥.美多巴联合普拉克索治疗帕金森病的有效性及安全性研究[J].中国生化药物杂志,2014,34(3):153-155. 被引量:46
  • 3邓怀福,胡平,陈萍.^(99)Tc^m-TRODAT-1 SPECT DAT显像与帕金森病UPDRS评分关系的研究[J].中国临床医学影像杂志,2005,16(2):64-66. 被引量:4
  • 4张振馨.帕金森病的诊断[J].中华神经科杂志,2006,39(6):408-409. 被引量:619
  • 5张国平,贺茂株,王莉莉,等.血管性帕金森综合征临床特点分析[J].中国全科医生,2012;24(8):2805-2806.
  • 6HROMETZ SL, SHIELDS KM. Role of ambrisentan in the management of pulmonary hypertension [J]. Ann Pharmacother,2008, 42(11): 1653-1658.
  • 7STRANGE G, KEOGH A, DEALTON B, et al. Pharmacoeconomic evidence of bosentan for pulmonary arterial hypertension[J]. Expert Rev Pharmacoeeon Outcomes Res, 2011, 11(3): 253-263.
  • 8GALIE N, HOEPER MM, HUMBERT M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension : the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT) [J]. Eur Heart J, 2009, 30(20) : 2493-2537.
  • 9BRAZIER JE, HARPER R, JONES NM, et al. Validating the SF- 36 health survey questionnaire: new outcome measure for primary care[J]. BMJ, 1992, 305(6846): 160-164.
  • 10GALIE N, RUBIN LJ, HOEPER M, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double- blind, randomized controlled triM[J]. Lancet, 2008, 371(9630): 2093-2100.

引证文献18

二级引证文献148

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部